CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 600 target
Drug / intervention
Alectinib - Usual +1 moredrug
Likely dose
Alectinib - Usual 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05987956
NCT05987956Phase 2ActiveOn Track
CompareCT.gov

Explore the Relationship Between Single Nucleotide Polymorphisms and Alectinib Response and Toxicity in Patients With Non-Small Cell Lung Cancer.

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·interventional·Posted Aug 14, 2023·Updated Jun 16, 2026

In Brief

A Phase 2 clinical trial evaluating Alectinib - Usual and Alectinib - Study for ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Active but no longer recruiting, targeting 600 participants across 2 sites.

Detailed Summary

Explore the relationship between drug target ALK gene single nucleotide polymorphisms and ALECENSA - Alectinib therapeutic-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and ALECENSA - Alectinib side-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsALK-Positive Non-Small Cell Lung Cancer (NSCLC)
CountriesUnited States
CollaboratorsUnitedHealthcare, Omnicure Clinical Research

Timeline

Phase 2Active
2024202520262027
First PostedAug 14, 2023
Enrollment StartMar 18, 2026
Primary CompletionNov 18, 2026
Study CompletionDec 28, 2026
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 2.9 years agoPrimary completion in 5 months

Arms & Interventions

Alectinib - Usualexperimental

* Usual ALECENSA - Alectinib * Chemotherapy (NDC...01) * Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily * Usual Approach Group (NDC...01) * ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily

Drug: Alectinib - Usual
Alectinib - Studyexperimental

* Study ALECENSA - Alectinib * Chemotherapy (NDC...86) * Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily * Study Approach Group (NDC...86) * ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily

Drug: Alectinib - Study

Interventions

Alectinib - Usualdrug

Usual Alectinib Chemotherapy (NDC...01) \- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily

Alectinib - Studydrug

Study Alectinib Chemotherapy (NDC...86) \- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily